Financings In Brief: Texas Biotechnology
Executive Summary
Texas Biotechnology: Subsidiary ImmunoPharmaceutics achieves technical milestone in a September 1993 computer-aided drug design agreement with the Japanese firm Eisai. The milestone triggered an additional research payment of $2 mil., the Houston-based cardiovascular biotech products R&D firm reports. The Eisai therapeutic target has not been disclosed...